BAT 8006
Alternative Names: BAT-8006Latest Information Update: 16 Aug 2024
At a glance
- Originator Bio-Thera Solutions
- Class Alkaloids; Antineoplastics; Camptothecins; Drug conjugates; Immunoconjugates; Monoclonal antibodies; Small molecules
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Solid tumours
Most Recent Events
- 09 Aug 2024 Bio-Thera Solutions plans a phase I/II trial for Ovarian cancer (Late-stage disease, Metastatic disease) (IV, Infusion) in September 2024 (NCT06545617)
- 02 Jun 2024 NMPA approves clinical trial application for BAT 8006 in Solid tumours (Combination therapy)
- 02 Jun 2024 Efficacy and adverse events data from a phase I trial in Solid tumors released by Bio-Thera Solutions